

2021 BIDMC Gram-Positive Antibiogram

How to Use:

-Click on the desired organism to highlight the antibiotic sensitivities below.

-To select for multiple organisms, hold ctrl

Gram-Positive Organisms	Occurrence
BETA STREPTOCOCCUS GROUP B	**30**
ENTEROCOCCUS SPP (including E. faecalis & E. faecium)	**821**
ENTEROCOCCUS FAECALIS	312
ENTEROCOCCUS FAECIUM	202
ENTEROCOCCUS SPP	307
STAPHYLOCOCCUS AUREUS (all)	**716**
STAPHYLOCOCCUS AUREUS-MRSA	242
STAPHYLOCOCCUS AUREUS-MSSA	475
STAPHYLOCOCCUS, COAGULASE NEGATIVE	**383**
STREPTOCOCCUS ANGINOSUS (MILLERI) GROUP	**85**

Methodology: Only the first isolate per patient per year is included for the antibiogram year in accordance with CLSI m39-A4E recommendations. Only cultures for diagnostic purposes are included. The BIDMC Antibiogram includes isolates from all inpatient units & emergency department.

Antibiotic name / Gram-Positive Organisms	AMPICILLIN n	AMPICILLIN %	CLINDAMYCIN n	CLINDAMYCIN %	DAPTOMYCIN^ n	DAPTOMYCIN^ %	GENTAMICIN n	GENTAMICIN %	LEVOFLOXACIN n	LEVOFLOXACIN %	LINEZOLID n	LINEZOLID %	NITROFURANTOIN* n	NITROFURANTOIN* %	OXACILLIN n	OXACILLIN %	PENICILLIN G n	PENICILLIN G %	TETRACYCLINE n	TETRACYCLINE %	TRIM/SULFA n	TRIM/SULFA %	VANCOMYCIN n	VANCOMYCIN %
BETA STREPTOCOCCUS GROUP B			**30**	**40%**													**30**	**100%**					**30**	**100%**
ENTEROCOCCUS SPP (including E. faecalis & E. faecium)	**819**	**67%**			**173**	**95%**					**297**	**99%**	**504**	**75%**			**316**	**61%**	**515**	**20%**			**821**	**67%**
ENTEROCOCCUS FAECALIS	**312**	**100%**			**80**	**96%**					**54**	**100%**	**170**	**99%**			**143**	**100%**	**175**	**18%**			**312**	**88%**
ENTEROCOCCUS FAECALIS-VRE	36	100%									36	100%											36	0%
ENTEROCOCCUS FAECALIS-VSE	276	100%			68	97%							151	99%			126	100%	154	19%			276	100%
ENTEROCOCCUS FAECIUM	**202**	**8%**			**92**	**93%**					**159**	**99%**	**84**	**24%**			**118**	**9%**	**90**	**19%**			**202**	**24%**
ENTEROCOCCUS FAECIUM-VRE	153	1%			73	95%					152	99%	65	25%			88	0%	70	17%			154	0%
ENTEROCOCCUS FAECIUM-VSE	50	30%															31	35%					49	100%
ENTEROCOCCUS SPP	**305**	**73%**									**84**	**98%**	**250**	**76%**			**55**	**71%**	**250**	**23%**			**307**	**73%**
STAPHYLOCOCCUS AUREUS (all)			**666**	**68%**	**73**	**100%**	**716**	**99%**	**704**	**75%**	**46**	**100%**	**50**	**98%**	**716**	**66%**			**569**	**91%**	**716**	**97%**	**252**	**100%**
STAPHYLOCOCCUS AUREUS-MRSA			**223**	**56%**	**61**	**100%**	**241**	**98%**	**232**	**38%**	**38**	**100%**			**242**	**0%**			**186**	**85%**	**241**	**94%**	**241**	**100%**
STAPHYLOCOCCUS AUREUS-MSSA			**443**	**75%**			**475**	**99%**	**472**	**94%**			**31**	**97%**	**475**	**100%**			**383**	**94%**	**475**	**99%**		
STAPHYLOCOCCUS, COAGULASE NEGATIVE			**305**	**57%**	**48**	**100%**	**383**	**81%**	**375**	**60%**	**32**	**100%**	**72**	**99%**	**383**	**40%**			**217**	**85%**			**383**	**100%**
STREPTOCOCCUS ANGINOSUS (MILLERI) GROUP			**85**	**69%**													**84**	**86%**					**85**	**100%**

Nitrofurantoin* for urine isolates only

^ % susceptible for E. faecium includes susceptible dose dependent for daptomycin

Streptococcus pneumoniae isolates over the past 2 years

Antibiotic	Ceftriaxone			Penicillin			Penicillin (oral)		
Type	n	MIC	%	n	MIC	%	n	MIC	%
meningitis	48	<=0.5	90.0%	48	<=0.06	60.0%			
non-meningitis	48	<=0.5	90.0%	48	<=2	96.0%	48	<=0.06	60.0%

2021 Gram-Negative Antibiogram | 2021 Gram-Positive Antibiogram

Presentation Type:
Poster Presentation - Poster Presentation
Subject Category: Antibiotic Stewardship
Creating an electronic antibiogram using visualization software: Easily updatable and removes the need for yearly manual review
Ashley Dauphin; Christopher McCoy; Robert Bowden; Matthew Lee; Howard Gold and Ryan Chapin

Background: Previously, our hospital manually built a static antibiogram from a surveillance system (VigiLanz) culture report. In 2019, a collaboration between the antimicrobial stewardship team (AST) and the infection control (IC) team set out to leverage data automation to create a dynamic antibiogram. The goal for the antibiogram was the ability to easily distribute and update for hospital staff, with the added ability to perform advanced tracking and surveillance of organism and drug susceptibilities for AST and IC. By having a readily available, accurate, and Clinical and Laboratory Standards Institute (CLSI)–compliant antibiogram, clinicians have the best available data on which to base their empiric antibiotic decisions. **Methods:** First, assessment of required access to hospital databases and selection of a visualization software (MS Power BI) was performed. Connecting SQL database feeds to Power BI enabled creation of a data model using DAX and M code to comply with the CLSI, generating the first isolate per patient per year. Once a visual antibiogram was created, it was validated against compiled antibiograms using data from the microbiology laboratory middleware (bioMerieux, Observa Integrated Data Management Software). This validation process uncovered some discrepancies between the 2 reference reports due to cascade reporting of susceptibilities. The Observa-derived data were used as the source of truth. The antibiogram prototype was presented to AST/IC members, microbiology laboratory leadership, and other stakeholders to assess functionality. **Results:** Following feedback and revisions by stakeholders, the new antibiogram was published on a hospital-wide digital platform (Fig. 1). Clinicians may view the antibiogram at any time on desktops from a firewall (or password)–protected intranet. The antibiogram view defaults to the current calendar year and users may interact with the antibiogram rows and columns without disrupting the integrity of the background databases or codes. Each year, simple refreshing of the Power BI antibiogram and changing of the calendar year allows us to easily and accurately update the antibiogram on the hospital-wide digital platform. **Conclusions:** This interdisciplinary collaboration resulted in a new dynamic, CLSI-compliant antibiogram with improved usability, increased visibility, and straightforward updating. In the future, a mobile version of the antibiogram may further enhance accessibility, bring more useful information to providers, and optimize AST/IC guidelines and education.
Disclosures: None

Antimicrobial Stewardship & Healthcare Epidemiology 2023;3(Suppl. S2):s34
doi:10.1017/ash.2023.262

Presentation Type:
Poster Presentation - Poster Presentation
Subject Category: Antibiotic Stewardship
Identifying the relationship between hospital rurality and antibiotic overuse
Hannah Hardin; Valerie Vaughn; Andrea White; Jennifer Horowitz; Elizabeth McLaughlin; Julia Szymczak; Lindsay Petty; Anurag Malani; Scott Flanders and Tejal Gandhi

Background: Antibiotic overuse and the resulting patient outcomes span all hospitals. However, although antibiotic stewardship can improve antibiotic use, effective stewardship programs require expertise and an infrastructure that are not present in all hospitals. Rural hospitals have less access to resources, infectious disease expertise, and participation in academic research. Thus, we compared antibiotic overuse at discharge between rural and nonrural hospitals for patients diagnosed with community-associated pneumonia (CAP) or urinary tract infection (UTI)—the 2 most common hospital infections. **Methods:** To determine whether antibiotic overuse at discharge was higher among rural versus nonrural hospitals, we analyzed data from a 41-hospital prospective cohort of patients treated for CAP or UTI between July 1, 2017, and July 30, 2019, in Michigan. Antibiotic overuse was defined as treatment that was unnecessary (ie, patient did not have an infection), excessive (ie, duration >4 days for CAP), or included suboptimal fluoroquinolone use (ie, safer alternative available). Overuse was determined based on patient risk